Pharmaceuticals Company Reports Positive Clinical Data Results For Brain Cancer Treatment

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) recently announced promising results from a Phase 1 study of MTX110, an investigational drug for the treatment of Diffuse Midline Glioma (DMG), also known as Diffuse Intrinsic Pontine Glioma (DIPG). These results were presented at the 21st International Symposium on Pediatric Neuro-Oncology (ISPNO 2024) held in Philadelphia, PA. This article delves into the details of the study, the results obtained, and the potential implications for future treatments of this orphan pediatric brain cancer. $Biodexa Pharmaceuticals(BDRX.US)$